Literature DB >> 8145903

Large cerebral vessel occlusive disease in systemic lupus erythematosus.

P Mitsias1, S R Levine.   

Abstract

We systematically investigated clinical, laboratory, radiologic, and pathologic features, including treatment and prognosis, of stroke syndromes in 30 patients, six from our institution and 24 from the literature, with systemic lupus erythematosus (SLE) and symptomatic large cerebral vessel occlusive disease, documented by angiography or autopsy. The average age at stroke onset was 35 years, and the diagnosis of SLE was made on average 4.4 years prior to that. At least 86% had active SLE at the time of their stroke. Headache was common at onset. We found major intracranial or extracranial vessel occlusive process by (1) thrombus, (2) dissection, (3) fibromuscular dysplasia or vasculitis, and (4) atherosclerosis. The presumed mechanisms were coagulopathy, cardiogenic embolism, large cerebral vessel vasculitis or occlusive vasculopathy, cervical arterial dissection, and premature atherosclerosis. The short-term death rate was 40% and the recurrent stroke rate was 13%. We conclude that symptomatic large cerebral vessel occlusive disease in SLE generally occurs several years after the diagnosis of SLE, usually during the active phase of the disease, is related to heterogeneous mechanisms, and carries a relatively poor short-term outcome.

Entities:  

Mesh:

Year:  1994        PMID: 8145903     DOI: 10.1212/wnl.44.3_part_1.385

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  13 in total

1.  Cerebral leucocyte infiltration in lupus-prone MRL/MpJ-fas lpr mice--roles of intercellular adhesion molecule-1 and P-selectin.

Authors:  W G James; P Hutchinson; D C Bullard; M J Hickey
Journal:  Clin Exp Immunol       Date:  2006-05       Impact factor: 4.330

2.  Non-atherosclerotic vascular disease in the young.

Authors:  Osvaldo Camilo; Larry B Goldstein
Journal:  J Thromb Thrombolysis       Date:  2005-10       Impact factor: 2.300

3.  The histopathologic associates of neurometabolite abnormalities in fatal neuropsychiatric systemic lupus erythematosus.

Authors:  William M Brooks; Wilmer L Sibbitt; Mario Kornfeld; Rex E Jung; Arthur D Bankhurst; Carlos A Roldan
Journal:  Arthritis Rheum       Date:  2010-07

4.  Magnetic resonance imaging and brain histopathology in neuropsychiatric systemic lupus erythematosus.

Authors:  Wilmer L Sibbitt; William M Brooks; Mario Kornfeld; Blaine L Hart; Arthur D Bankhurst; Carlos A Roldan
Journal:  Semin Arthritis Rheum       Date:  2009-10-31       Impact factor: 5.532

5.  Cerebrovascular Complications of Fibromuscular Dysplasia.

Authors:  Megan C. Leary; Anna Finley; Louis R. Caplan
Journal:  Curr Treat Options Cardiovasc Med       Date:  2004-06

Review 6.  Controversies in lupus: nervous system involvement.

Authors:  G A Bruyn
Journal:  Ann Rheum Dis       Date:  1995-03       Impact factor: 19.103

7.  Treatment of moyamoya syndrome associated with systemic lupus erythematosus and hypothyroidism in an adult by encephaloduroarteriosynangiosis: a case report.

Authors:  Arata Tomiyama; Hitoshi Kimura; Haruo Nakayama; Hideaki Izukura; Jun-Ichi Harashina; Keisuke Ito; Ken-Ichiro Sato; Morito Hayashi; Norihiko Saito; Takatoshi Sakurai; Yoko Hirata; Kazuya Aoki; Satoshi Iwabuchi
Journal:  Case Rep Med       Date:  2012-08-26

8.  Moyamoya syndrome occurred in a girl with an inactive systemic lupus erythematosus.

Authors:  Yun-Jin Lee; Gyu Min Yeon; Sang Ook Nam; Su Yung Kim
Journal:  Korean J Pediatr       Date:  2013-12-20

9.  Extensive vascular occlusions as initial presentations of systemic lupus erythematosis. A case report and review of literature.

Authors:  Mohamed Elsharawy; Manal Hasan; Ibrahiem Saeed Abdul-Rahman; Bandar Al-Dhofairy; Ayman Elsaid
Journal:  Avicenna J Med       Date:  2015 Apr-Jun

10.  Cardiovascular disease in systemic lupus erythematosus: the role of traditional and lupus related risk factors.

Authors:  Carlos Borelli Zeller; Simone Appenzeller
Journal:  Curr Cardiol Rev       Date:  2008-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.